UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1176-10
Program Prior Authorization/Notification
Medication Strensiq™ (asfotase alfa)
P&T Approval Date 2/2016, 12/2016, 11/2017, 11/2018, 11/2019, 11/2020, 11/2021,
11/2022, 11/2023, 10/2024
Effective Date 1/1/2025
1. Background:
Strensiq (asfotase alfa) is a tissue nonspecific alkaline phosphatase indicated for the treatment of
patients with perinatal/infantile and juvenile-onset hypophosphatasia (HPP).
2. Coverage Criteriaa:
A. Initial Authorization
1. Strensiq will be approved based on one of the following criteria:
a. Diagnosis of perinatal/infantile-onset hypophosphatasia
-OR-
b. Diagnosis of juvenile-onset hypophosphatasia
Authorization will be issued for 12 months.
B. Reauthorization
1. Strensiq will be approved based on the following criterion:
a. Documentation of positive clinical response to Strensiq therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
© 2024 UnitedHealthcare Services, Inc.
1
4. References:
1. Strensiq [package insert]. Boston, MA: Alexion Pharmaceuticals, Inc.; July 2024.
Program Prior Authorization/Notification - Strensiq (asfotase alfa)
Change Control
2/2016 New program.
12/2016 Annual Review. Revised background. Extended initial authorization to
12 months.
11/2017 Annual Review. Updated references.
11/2018 Annual Review. Updated references.
11/2019 Annual Review. No changes.
11/2020 Annual review. Updated reference.
11/2021 Annual review with no changes to clinical coverage criteria.
11/2022 Annual review with no changes to clinical coverage criteria. Added
state mandate footnote.
11/2023 Annual review with no changes to clinical coverage criteria.
10/2024 Annual review with no changes to clinical coverage criteria. Updated
reference.
© 2024 UnitedHealthcare Services, Inc.
2